Board approves Q1 FY27 results, appoints cost auditor, AGM on 21 Aug
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Oxygenta Pharmaceutical board met on 27 July 2026 and approved Q1 FY27 results. Total revenue rose sharply to Rs. 3,702 lakhs from Rs. 1,530 lakhs year-on-year. Net loss narrowed to Rs. 210 lakhs from Rs. 611 lakhs. EPS stood at negative Rs. 0.57. The board appointed PCR and Associates as cost auditor for FY 2026-27. AGM for FY 2025-26 is set for 21 August 2026 via video conferencing. The company also reconstituted its POSH committee and availed Rs. 399 lakhs under the ECLGS scheme.
Revenue nearly doubled and loss narrowed sharply, indicating operational improvement, though the company remains in the red.